1 / 6

Anaplastic Large Cell Lymphoma Pipeline therapeutics Assessment Review H2 2015

This report provides comprehensive information on the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and special features on late-stage and discontinued projects

sarakidman2222
Télécharger la présentation

Anaplastic Large Cell Lymphoma Pipeline therapeutics Assessment Review H2 2015

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 26-Aug-2015 No. of pages: 104 Single User License: US $2000 Browse more Reports on Cancer Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: Akron Molecules AG, AstraZeneca Plc, Bayer AG, Celon Pharma Sp. z o.o., Pfizer Inc., Sareum Holdings Plc, Seattle Genetics, Inc. and Teva Pharmaceutical Industries Limited Drugs Profile Discussed in this Research: AdIL-24, AKR-302, AKR-303, AZD-3463, brentuximabvedotin, CEP-28122, CEP-37440, copanlisib hydrochloride, crizotinib, Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma, KRA-0008, SH-7129, Small Molecules to Inhibit Aurora and ALK Kinase for Oncology and Small Molecules to Inhibit Aurora Kinase and FLT3 Kinase for Oncology ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015 Scope For Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL) • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Anaplastic Large Cell Lymphoma (ALCL) and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Anaplastic Large Cell Lymphoma (ALCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015 Reasons to Buy: • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL) • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related